NEOGENOMICS INC — Director's Dealing 2017

Mar 22, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2017-03-13

Reporting Person: BRODIE STEVEN G. (President, Pharma Services)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-13	Common Stock	S	16550	$8.00	Disposed	49403	Direct
2017-03-20	Common Stock	S	33450	$7.90	Disposed	15953	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$3.76	2018-04-16	Common Stock (10000)	10000	Direct
Stock Option (Right to Buy)	$3.45	2019-03-05	Common Stock (20000)	20000	Direct
Stock Option (Right to Buy)	$4.78	2020-05-04	Common Stock (120000)	120000	Direct
Stock Option (Right to Buy)	$7.15	2021-04-20	Common Stock (100000)	100000	Direct

Footnotes

F1: This line is included for purposes of amending the filing on 3/17/2017 which inadvertently showed the transaction as securities acquired rather than securities disposed of.

F2: On April 16, 2013 Dr. Brodie was granted 10,000 stock options. These options will vest ratably over the next three anniversary dates of the grant dates.

F3: On March 5, 2014 Dr. Brodie was granted 20,000 stock options. The options will vest ratably over the next three anniversary dates of the grant date.

F4: On May 4, 2015 Dr, Brodie was granted 120,000 stock options. These options vest ratably over the next three anniversary dates of the grant date.

F5: On April 20, 2016, Mr. Brodie was granted 100,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.